Table 1.
Providing an overview of compounds and their roles as autophagy modulators HCC research. Abbreviations: chloroquine (CQ), hydroxychloroquine (HCQ).
| Compounds | Autophagy Modulators | Experimental Objects | Mechanism |
|---|---|---|---|
| CQ | Inhibitor | HCC cell line: HepG2 [241] | Lysosomal Inhibitor |
| HCQ | Inhibitor | HCC cell lines: HepG2 and Huh7 [242] | |
| BafA1 | Inhibitor | Rat liver cell line H-4-II-E [203] | V-ATPase Inhibitor |
| HCC cell lines: (BEL7402, LO2, SMMC-7721, Huh7, and HepG2) [204] | |||
| 3-methyladenine plus delphinidin | Inhibitor | HCC cell line: SMMC7721 [209] | PI3K Inhibitors |
| LY294002 | Inhibitor | Normal liver cell line: HL-7702 [210] HCC cell lines: SMMC-7721, BEL-7401, SK-Hep-1 and HEP-G2 [210] |
|
| VPS34-IN-1 | Inhibitor | HCC cell line: Huh7, MHCC-97H [217] | VPS34 Inhibitor |
| MRT68921 plus Cinobufagin | Inhibitor | HCC cell line: HepG2 and Huh7 [221] | ULK1/2 Inhibitor |
| SBI-0206965 | Inhibitor | Normal human liver cells (L02) [227] Nutrient-starved human HCC [227] |
|
| DC-ATG4in | Inhibitor | HCC cell lines: Huh7 and SK-HEP-1 [230] | ATG4B Inhibitor |
| Temsirolimus plus Sorafenib |
Activator | HCC patients [238] | mTOR inhibitor |
| Everolimus plus Sorafenib |
Activator | HCC patients [239] |